United Kingdom monkeypox therapeutics market is expected to register robust growth in the forecast period, 2023-2027. As per the Disease Control and Prevention (CDC), Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus.  Monkeypox represents a viral disease, is spreading across Europe and North America at a high growth rate. The illness causes fever, intense headaches and swollen lymph nodes and has a fatality ratio of three to six percent, as per the World Health Organization (WHO). This disease spreads from one person to another by having a close contact with respiratory secretions and skin lesions. Transmission via droplet respiratory particles generally requires prolonged face-to-face contact, which puts health workers, household members and other close contacts of active cases at greater risk. These risks can be minimized

Growing Population with Weak Immunization Augments the Market Growth

The expanding population across the United Kingdom is driving the risk of catching monkeypox especially those who have weak immune systems. The increase in number of cases of monkeypox is escalating the need for therapeutics which supports the market growth. Along with this, people with weak immune system can get the severe symptoms which sometimes can lead to death. This, in turn, is anticipated to accelerate the growth of the monkeypox therapeutics market across United Kingdom.

Extensive R & D Activities to Manufacture Emergency Drugs Catalyze the Market Growth

The high-quality visualization provided by proper diagnosis allows physicians to detect, and diagnose, is acting as significant growth-inducing factor. The spread of monkeypox at a high rate is propelling the need for emergency drugs for the effective treatment at the right time is bolstering the growth of the market. Additionally, researchers across United Kingdom continuously making efforts to produce drugs in huge amount for providing it to the maximum patients. With this, research and development activities require extensive investments on advance equipment and technologies to support the drug development to combat with the outbreak of monkeypox across the globe. This, in turn, is anticipated to fuel the growth of the monkeypox market.

Expanding Healthcare Infrastructure is Expected to Boost the Market Growth

The enhancing infrastructure and the easy access to the healthcare facilities are some of the significant growth-inducing factors for the monkeypox therapeutics market. United Kingdom offers advanced and upgraded healthcare facilities to their citizens that make people aware of numerous diseases. Also, the rising awareness among the people regarding the monkeypox virus is driving the need to be tested if facing any symptoms. This further inflates the demand for hospitals or clinics for the effective treatment. All these aforementioned factors estimated to witness the growth for monkeypox therapeutics market across United Kingdom.


DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The United Kingdom monkeypox therapeutics market is segmented into treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is divided into smallpox vaccine, antivirals, vaccinia immune globulin (VIG). Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, others. To analyze the market based on the region, the United Kingdom monkeypox therapeutics market is studied in major regions namely London, Southeast, East Anglia, Scotland, Southwest, East Midlands, Yorkshire & Humberside, Rest of United Kingdom.

Market Players

Chimerix UK Limited, SIGA Technologies, Inc., Emergent BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon S.p.A., Teva UK Limited are the key market players operating in United Kingdom monkeypox therapeutics market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Treatment

·         End User

·         Region

Regional scope

 

London, Southeast, East Anglia, Scotland, Southwest, East Midlands, Yorkshire & Humberside, Rest of United Kingdom

Key companies profiled

Chimerix UK Limited, SIGA Technologies, Inc., Emergent BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon S.p.A., Teva UK Limited

Customization scope

10% free report customization with purchase. Addition or alteration to regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, United Kingdom monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         United Kingdom Monkeypox Therapeutics Market, By Treatment:

o   Smallpox Vaccine

o   Antivirals

o   Vaccinia Immune Globulin (VIG)

·         United Kingdom Monkeypox Therapeutics Market, By End User:

o   Hospitals

o   Specialty Clinics

o   Ambulatory Surgical Centers

o   Others

·         United Kingdom Monkeypox Therapeutics Market, By Region:

o   London

o   Southeast

o   East Anglia

o   Scotland

o   Southwest

o   East Midlands

o   Yorkshire & Humberside

o   Rest of United Kingdom 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United Kingdom monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

o   Detailed analysis and profiling of additional market players (up to five).

United Kingdom monkeypox therapeutics market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United Kingdom Monkeypox Therapeutics Market

4.    Executive Summary

5.    Voice of Customer

6.    United Kingdom Monkeypox Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1. By Value

6.2.  Market Share & Forecast

6.2.1.     By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))

6.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.3. By Region

6.2.4. By Company (2021)

6.3.  Product Market Map

7.    London Monkeypox Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1. By Value

7.2.  Market Share & Forecast

7.2.1. By Treatment

7.2.2. By End User

8.    East Anglia Monkeypox Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1. By Value

8.2.  Market Share & Forecast

8.2.1. By Treatment

8.2.2. By End User

9.    Southwest Monkeypox Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1. By Value

9.2.  Market Share & Forecast

9.2.1. By Treatment

9.2.2. By End User

10.  Southeast Monkeypox Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.    By Value

10.2.              Market Share & Forecast

10.2.1.    By Treatment

10.2.2.    By End User

11.  Scotland Monkeypox Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.    By Value

11.2.              Market Share & Forecast

11.2.1.    By Treatment

11.2.2.    By End User

12.  East Midlands Monkeypox Therapeutics Market Outlook

12.1.              Market Size & Forecast

12.1.1.    By Value

12.2.              Market Share & Forecast

12.2.1.    By Treatment

12.2.2.    By End User

13.  Yorkshire & Humberside Monkeypox Therapeutics Market Outlook

13.1.              Market Size & Forecast

13.1.1.    By Value

13.2.              Market Share & Forecast

13.2.1.    By Treatment

13.2.2.    By End User

14.  Market Dynamics

14.1.              Drivers

14.2.              Challenges

15.  Market Trends & Developments

16.  Policy & Regulatory Landscape

17.  Import-Export Analysis

18.  United Kingdom Economic Profile

19.  Competitive Landscape

19.1.              Chimerix UK Limited

19.2.              SIGA Technologies, Inc.

19.3.              Emergent BioSolutions UK Ltd.

19.4.              Bavarian Nordic A/S

19.5.              Mylan N.V.

19.6.              Olon S.p.A.

19.7.              Teva UK Limited

20. Strategic Recommendations

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com